ROS1-targeted therapies, such as crizotinib and other ROS1 inhibitors, have demonstrated significant antitumor activity and have become an approved treatment option for patients with ROS1-positive advanced NSCLC. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.